$160.83
2.43% yesterday
Nasdaq, Dec 23, 10:00 pm CET
ISIN
US5011471027
Symbol
KRYS

Krystal Biotech, Inc. Stock price

$160.83
-33.73 17.34% 1M
-17.43 9.78% 6M
+36.77 29.64% YTD
+37.00 29.88% 1Y
+88.50 122.36% 3Y
+102.28 174.69% 5Y
+150.19 1,411.56% 10Y
Nasdaq, Closing price Mon, Dec 23 2024
-4.00 2.43%
ISIN
US5011471027
Symbol
KRYS
Sector
Industry

Key metrics

Market capitalization $4.63b
Enterprise Value $4.04b
P/E (TTM) P/E ratio 90.98
EV/FCF (TTM) EV/FCF 69.66
EV/Sales (TTM) EV/Sales 16.75
P/S ratio (TTM) P/S ratio 19.15
P/B ratio (TTM) P/B ratio 5.22
Revenue growth (TTM) Revenue growth 2,722.79%
Revenue (TTM) Revenue $241.52m
EBIT (operating result TTM) EBIT $64.95m
Free Cash Flow (TTM) Free Cash Flow $58.06m
Cash position $588.32m
EPS (TTM) EPS $1.77
P/E forward 45.18
P/S forward 15.88
EV/Sales forward 13.88
Short interest 16.73%
Show more

Is Krystal Biotech, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.

Krystal Biotech, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Krystal Biotech, Inc. forecast:

10x Buy
100%

Analyst Opinions

10 Analysts have issued a Krystal Biotech, Inc. forecast:

Buy
100%

Financial data from Krystal Biotech, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
242 242
2,721% 2,721%
100%
- Direct Costs 25 25
411% 411%
10%
217 217
5,701% 5,701%
90%
- Selling and Administrative Expenses 94 94
5% 5%
39%
- Research and Development Expense 51 51
15% 15%
21%
72 72
155% 155%
30%
- Depreciation and Amortization 6.59 6.59
44% 44%
3%
EBIT (Operating Income) EBIT 65 65
148% 148%
27%
Net Profit 52 52
276% 276%
22%

In millions USD.

Don't miss a Thing! We will send you all news about Krystal Biotech, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Krystal Biotech, Inc. Stock News

Neutral
GlobeNewsWire
6 days ago
Preliminary clinical data in post-anti-PD-1 NSCLC patients demonstrated a 27% ORR and 73% DCR in monotherapy trial Monotherapy activity with inhaled KB707 provides further evidence of successful repeat administration of HSV-1 based inhaled lung gene delivery and builds on recent clinical data update for CF and AAT deficiency respiratory disease programs PITTSBURGH, Dec. 18, 2024 (GLOBE NEWSWIRE...
Neutral
GlobeNewsWire
14 days ago
CHMP opinion now expected in 1Q 2025 No Major Objections outstanding; continue to expect Germany launch in 2Q 2025 PITTSBURGH, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) cancelled the Oral Expla...
Neutral
GlobeNewsWire
27 days ago
PITTSBURGH, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in fireside chats and host investor meetings at two upcoming investor conferences:
More Krystal Biotech, Inc. News

Company Profile

Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.

Head office United States
CEO Krish Krishnan
Employees 229
Founded 2016
Website www.krystalbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today